We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novavax signed a licensing agreement with the Serum Institute of India yesterday to commercialize the drugmaker’s COVID-19 vaccine candidate in low- and middle-income countries, as well as in India. Read More
AstraZeneca (AZ) has reached an agreement with China’s Kangtai Biologics to help develop and manufacture its promising coronavirus candidate AZD1222, the first deal the British drugmaker has forged for its experimental vaccine in China. Read More
Moderna is offering its COVID-19 vaccine candidate at $32 to $37 per dose for smaller-scale supply agreements, the company’s CEO Stéphane Bancel said Wednesday. Read More
Johnson & Johnson (J&J) has secured a $1 billion contract from the U.S. government to manufacture 100 million doses of its COVID-19 vaccine candidate Ad26.COV2.S. Read More
Pfizer and BioNTech have signed an agreement with Japan’s Ministry of Health to supply the country with 120 million doses of their COVID-19 vaccine. Read More
Sanofi and GlaxoSmithKline (GSK) have secured a $2.1 billion U.S. government contract to develop and produce 100 million doses of their COVID-19 vaccine candidate. Read More